Senti Biosciences Holdings
SNTI
15 hedge funds and large institutions have $14.2M invested in Senti Biosciences Holdings in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
3.07% more ownership
Funds ownership: 22.77% → 25.84% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 16 → 15 (-1)
28% less capital invested
Capital invested by funds: $19.9M → $14.2M (-$5.66M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.82M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$655K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$372K |
| 4 |
BlackRock
New York
|
+$57.2K |
| 5 |
Barclays
London,
United Kingdom
|
+$1.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
-$1.17M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$124K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$21.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$962 |
| 5 |
JP Morgan Chase
New York
|
-$30 |
SNTI Hedge Fund Activity: Q2 2025 in Review
15 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q2 2025, worth a combined $14.2M — down 28% from $19.9M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SNTI and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.82M. The largest seller was Heights Capital Management, cutting an estimated $1.17M.
- 15 institutional investors held Senti Biosciences Holdings (SNTI) as of Q2 2025, down from 16 in Q1 2025.
- Funds reported $14.2M of Senti Biosciences Holdings stock for Q2 2025, down 28% quarter-over-quarter.
- 1 fund opened new Senti Biosciences Holdings positions in Q2 2025 and 2 closed out, a net change of -1 holder.
- The largest Senti Biosciences Holdings buyer in Q2 2025 was Armistice Capital, an estimated $2.82M added.
- The largest Senti Biosciences Holdings seller in Q2 2025 was Heights Capital Management, an estimated $1.17M sold.
Based on aggregated 13F filings for Q2 2025.